| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. | |
| | |
MedLine Citation:
|
PMID: 13678869 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome. METHODS: Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat. FINDINGS: The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment. INTERPRETATION: The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction. |
| | |
Authors:
|
John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer; |
Related Documents
:
|
14564329 - Metoprolol cr/xl in postmyocardial infarction patients with chronic heart failure: expe... 15530189 - Postoperative fluid balance influences the need for antihypertensive therapy following ... 2341919 - Clinical predictors of treatment reduction in hypertensive patients. 16727759 - M-mode ultrasonic assessment of equine fetal heart rate. 7721419 - Comparison of effects of angiotensin i-converting enzyme inhibition and beta-blockade f... 11325669 - Long-term comparison between perindopril and nifedipine in normotensive patients with t... 2224429 - Chronic dehydration stone disease. 20535349 - The long-term clinical efficacy of biofeedback therapy for patients with constipation o... 9631999 - Papular dermatitis (subacute prurigo, "itchy red bump" disease): pilot study of phototh... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Lancet Volume: 362 ISSN: 1474-547X ISO Abbreviation: Lancet Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-09-18 Completed Date: 2003-10-27 Revised Date: 2013-05-28 |
Medline Journal Info:
|
Nlm Unique ID: 2985213R Medline TA: Lancet Country: England |
Other Details:
|
Languages: eng Pagination: 767-71 Citation Subset: AIM; IM |
Affiliation:
|
University of Glasgow, Glasgow, UK. j.mcmurray@bio.gla.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Angiotensin Receptor Antagonists Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Antihypertensive Agents / therapeutic use* Benzimidazoles / therapeutic use* Cardiac Output, Low / drug therapy, epidemiology, mortality Cardiovascular Diseases / mortality Comorbidity Drug Administration Schedule Drug Therapy, Combination Female Follow-Up Studies Heart Failure / drug therapy*, epidemiology, mortality Hospitalization Humans Male Placebos Tetrazoles / therapeutic use* Treatment Outcome Ventricular Dysfunction, Left / drug therapy*, epidemiology, mortality |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Placebos; 0/Tetrazoles; S8Q36MD2XX/candesartan |
| Comments/Corrections | |
Comment In:
|
ACP J Club. 2004 Mar-Apr;140(2):32-3
[PMID:
15122853
]
Lancet. 2003 Nov 15;362(9396):1675-6; author reply 1678-9 [PMID: 14630453 ] Lancet. 2003 Sep 6;362(9386):754-5 [PMID: 13678864 ] J Fam Pract. 2004 Feb;53(2):93-4 [PMID: 14764285 ] Lancet. 2003 Nov 15;362(9396):1677; author reply 1678-9 [PMID: 14630456 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-...
Next Document: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic ...